https://www.selleckchem.com/products/cpi-1205.html
Remdesivir is a nucleoside monophosphoramidate prodrug that has been FDA-approved for COVID-19. However, the clinical efficacy of remdesivir for COVID-19 remains contentious, as several trials have not found statistically significant differences in either time to clinical improvement or mortality between remdesivir-treated and control groups. Similarly, the inability for remdesivir to provide a clinically significant benefit above other investigational agents in patients with Ebola contrasts with strong, curative preclinical data gener
Like
Comment
Share
